Our key relationships

Autism Speaks

Neuropharm developed a collaboration agreement with the influential US patient organization Autism Speaks for the SOFIA (”Study of Fluoxetine in Autism”) multicenter trial of NPL–2008. The agreement has given Neuropharm access to Autism Speaks’ Clinical Trials Network of specialist pediatric centers and key opinion leaders, and served to expedite the enrollment of patients into the SOFIA trial in the US. Neuropharm funded the trial and, under the terms of the agreement, fully reimbursed Autism Speaks for its services.

To learn more about Autism Speaks, please visit www.autismspeaks.org.

The FRAXA Research Foundation (”FRAXA”)

Neuropharm has a collaboration agreement with FRAXA, the US not-for-profit organization for patients with Fragile X syndrome. The agreement gives Neuropharm access to FRAXA’s intellectual property rights, data and knowledge relating to the use of NPL–2009 to treat Fragile X syndrome. FRAXA worked with Neuropharm to help secure US Orphan Drug Designation for NPL–2009.

To learn more about FRAXA, please visit www.fraxa.org.

Catalent Pharma Solutions, formerly known as Cardinal Health Pharmaceutical Technologies (”Catalent”)

Catalent is the co-development and manufacturing partner for the “Zydis®” formulation of fluoxetine (NPL–2008) designed specifically for autistic patients. Neuropharm has an exclusive worldwide development and license agreement with Catalent for collaboration in respect of the development, licence, manufacture and supply to Neuropharm of the Zydis® formulation of fluoxetine.

Catalent has developed NPL-2008 in three dosage strengths.

Mount Sinai School of Medicine

In 2006 Neuropharm acquired the rights to the NPL-2008 program from the Mount Sinai School of Medicine in New York, where Professor Eric Hollander was granted Orphan Drug Designation in 1999 for the use of fluoxetine in autism.

Three completed trials of fluoxetine in autism have been carried out at Mount Sinai School of Medicine under Professor Hollander’s direction. Professor Hollander has been retained as a consultant to Neuropharm.